Home > PJ (current issue) > News / News Centre | Search

PJ Online homeThe Pharmaceutical Journal
Vol 279 No 7474 431
20 October 2007

This article
Reprint   Photocopy

  Acrobat Reader


News summary


Discount shops defy MHRA over paracetamol sales

Sales of multiple packs of analgesics are still taking place despite pressure from the Medicines and Healthcare products Regulatory Agency to try to persuade retailers to restrict sales to no more than two packs at a time.

This week, the agency announced that two retails chains, Poundland Ltd and The 99p Store, had refused to adopt what the MHRA describes as “responsible policies” over analgesic sales. Their stance has prompted a warning that the law could be tightened.

Jeremy Mean, policy group manager at the MHRA, said: “The Government has made clear that it will consider changing the law if retailers do not act responsibly. . . . With the right to sell medicines comes the responsibility to do so with care.”

An MHRA spokesman would not say whether Mr Mean’s statement should be interpreted as a threat to take action. “It’s an option open to us, should we need to go down that line,” he said.

However, The 99p Store has changed its policy after being asked to comment by The Pharmaceutical Journal.

Hussein Lalani, the company’s commercial director, said: “The 99p Store is a responsible retailer and would like to co-operate with the MHRA in the interest of public safety.”

He added that a change in the law would be a good idea because, he claimed, many retailers sold more than two packs in any one transaction, including at least one branch of Boots.

However, a Boots spokeswoman commented: “We have a till bar in place on all tills in Boots stores outside the health care area, which restricts the sale of more than two packets of 16 paracetamol in accordance with the MHRA guidelines. In the health care area and under the supervision of a pharmacist it is legal to sell up to 100 paracetamol tablets in accordance with [the Royal Pharmaceutical Society’s guide] ‘Medicines, Ethics and Practice’.”

Poundland Ltd did not respond to The Journal’s request for a comment.

Back to Top


©The Pharmaceutical Journal